Pain Management Programmes (PMPs) are recommended for chronic pain, but their effectiveness for endometriosis-associated chronic pelvic pain (CPP) remains unclear. This study evaluates outcomes from a specialised, multidisciplinary Pelvic Pain …
Endometriosis often presents in adolescence as chronic pelvic pain (CPP) or dysmenorrhea. Research in adults demonstrates non-White race is associated with delayed surgical diagnosis of endometriosis; however, inequity in adolescents …
Endometriosis is a gynecological condition which often causes chronic or recurrent pelvic pain (CPP). The disease can thereby impose a significant burden on affected individuals and their romantic relationships. Existing …
Chronic pelvic pain syndrome (CPPS) in women is a debilitating condition with a high prevalence (5-25%), yet its etiology remains unclear. This prospective observational study aimed to identify clinical and …
Objective: To comprehensively examine the qualitative results of current studies reporting the efficacy of digital health (DH) technologies in the treatment of chronic pelvic pain syndromes (CPPS) and to describe …
Background: An average time to diagnosis of 7 years is commonly described for endometriosis; diagnostic delay for adenomyosis is unknown. This cross-sectional study aimed to describe diagnostic delay for endometriosis …
Endometriosis is a chronic, hormone-dependent disease affecting up to 10% of women of reproductive age, often associated with chronic pelvic pain (CPP). Neuropathic pain has been increasingly recognized as a …
The goal was to develop a pragmatic classification system for conditions associated with chronic pelvic pain (CPP), aiming to enhance diagnosis, management, education, and research of CPP. An international, multidisciplinary …
Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …
Di(2-ethylhexyl) phthalate (DEHP), the most prevalent plasticizer worldwide, can enter the human body via various exposure pathways, including ingestion, inhalation, skin contact, and medical applications. It has been observed to …